Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on November 30, 2011, for Stereotaxis, Inc., a Delaware corporation. The filing details the entry into material definitive agreements regarding financing and the amendment of existing loan covenants.
Key Financial Metrics and Agreements
- New Financing: Entered into a Loan Agreement with Cowen Healthcare Royalty Partners II, L.P. for an initial principal of $15 million.
- Contingent Borrowing: Potential to borrow an additional $5 million based on sales milestones for the Niobe Epoch system in 2012 (up to $2.5 million by August 2012 and up to $5 million by February 2013).
- Interest Rate: The Cowen loan bears interest at an annual rate of 16%, payable quarterly.
- Maturity: The Cowen loan matures on December 31, 2018.
- Repayment Source: Repayment is secured by 100% of royalties due under the Development, Alliance and Supply Agreement with Biosense Webster, Inc., until the loan is repaid.
- Existing Debt Amendments: Amended the Loan and Security Agreement with Silicon Valley Bank (SVB) and the Export-Import Bank Agreement.
- Covenants: SVB agreement now requires a minimum tangible net worth of not less than ($17,500,000). The liquidity ratio covenant for the period ending January 31, 2012, was adjusted to not less than 1.25:1.00.
Material Changes and Unusual Items
The primary material change is the creation of a direct financial obligation via the royalty-backed loan with Cowen Royalty. This is a full recourse loan secured by specific assets and intellectual property. A unique feature of this loan is the interest capitalization clause: if royalty payments are insufficient to cover interest, the deficiency increases the outstanding principal. Additionally, the company satisfied a capital raise obligation under its original SVB agreement by November 30, 2011.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the achievement of sales milestones for the Niobe Epoch system, which are necessary to access the additional $5 million in funding. The company explicitly states that actual performance may differ materially from projections due to risks and uncertainties. The filing does not provide specific revenue or profit guidance for the upcoming fiscal periods, nor does it detail current cash flow or liquidity positions beyond the covenant requirements.
Investor Verification Checklist
- Verify the closing conditions for the $15 million Cowen loan and the timeline for funding (on or prior to December 5, 2011).
- Review the specific sales milestones required to unlock the additional $5 million in contingent borrowing.
- Assess the impact of the 16% interest rate and potential principal capitalization on future cash flows.
- Confirm the company's current tangible net worth against the new SVB covenant of ($17,500,000).
- Examine the Biosense Webster royalty agreement to understand the volatility of the repayment source.